Compass Therapeutics (NASDAQ:CMPX) Given "Buy" Rating at HC Wainwright

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $10.00 price target on the stock.

Separately, Wedbush reissued an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Friday, March 22nd.

Compass Therapeutics Trading Down 0.6 %

Shares of CMPX stock traded down $0.01 during trading hours on Tuesday, reaching $1.57. 718,709 shares of the company's stock were exchanged, compared to its average volume of 499,996. Compass Therapeutics has a 1 year low of $1.15 and a 1 year high of $3.62. The stock's fifty day moving average price is $1.84 and its two-hundred day moving average price is $1.73. The stock has a market cap of $216.02 million, a PE ratio of -4.61 and a beta of 0.78.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). On average, equities analysts expect that Compass Therapeutics will post -0.48 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. grew its holdings in Compass Therapeutics by 2.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 6,380,000 shares of the company's stock valued at $12,569,000 after buying an additional 130,000 shares in the last quarter. Blackstone Inc. grew its holdings in shares of Compass Therapeutics by 3.1% during the 3rd quarter. Blackstone Inc. now owns 6,189,551 shares of the company's stock worth $12,193,000 after purchasing an additional 188,811 shares during the period. BlackRock Inc. grew its holdings in shares of Compass Therapeutics by 291.5% during the 2nd quarter. BlackRock Inc. now owns 6,032,292 shares of the company's stock worth $19,183,000 after purchasing an additional 4,491,397 shares during the period. Braidwell LP boosted its holdings in Compass Therapeutics by 79.0% during the 1st quarter. Braidwell LP now owns 3,247,847 shares of the company's stock valued at $10,620,000 after acquiring an additional 1,433,581 shares during the period. Finally, Blue Owl Capital Holdings LP acquired a new stake in Compass Therapeutics in the 4th quarter valued at about $4,414,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.